Domagrozumab

Domagrozumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	GDF-8
Clinical data
Other names	PF-06252616
ATC code	none;
Identifiers
CAS Number	1629605-31-7 ;
ChemSpider	none;
UNII	516MD5WQ24 ;
KEGG	D11047 ;
Chemical and physical data
Formula	C6366H9826N1690O2008S46
Molar mass	143639.22 g·mol−1

Last updated April 02, 2025

Domagrozumab (PF-06252616) (INN) is a humanized monoclonal antibody designed for the treatment of Duchenne muscular dystrophy.^[1]^[2]

This drug was developed by Pfizer. Pfizer stopped development in 2018 after disappointing results in 2 human trials.^[3]

References

↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Domagrozumab, American Medical Association .
↑ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).
↑ "Pfizer Terminates Domagrozumab (PF-06252616) Clinical Studies for the Treatment of Duchenne Muscular Dystrophy | Pfizer". www.pfizer.com.

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Statement On A Nonproprietary Name Adopted By The USAN Council - Domagrozumab, American Medical Association .

[2] World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).

[3] "Pfizer Terminates Domagrozumab (PF-06252616) Clinical Studies for the Treatment of Duchenne Muscular Dystrophy | Pfizer". www.pfizer.com.

[1]

[2]

[3]